Selected Publications



Baldwin Lab Home

  • Sitcheran, R., P. Cogswell, and A. Baldwin (2003). NF-kB mediates inhibition of mesenchymal cell differentiation through a post-transcriptional gene silencing mechanism. Genes and Development, in press (October).

  • Anest, V., J. Hanson, P. Cogswell, K. Steinbrecher, B. Strahl, and A. Baldwin (2003). A nucleosomal function for IKKa in NF-kB-dependent gene expression. Nature 423:  659-663.

  • Hanson, J., V. Anest, and A. Baldwin (2003). Oncoprotein suppression of NF-kB activation by TNF is independent of Raf-controlled pathways. J. Biol. Chem., in press.

  • Reuther-Madrid, J., D. Kashatus, S. Chen, X. Li, J. Westwick, R. Davis, H. S. Earp, C.-Y. Wang, and A. Baldwin (2002). The p65/RelA subunit of NF-kB suppresses the sustained, antiapoptotic activity of Jun kinase induced by TNF. Mol. Cell. Biol. 22: 8175-8183.

  • Orlowski, R. and A. Baldwin (2002). NF-kB as a therapeutic target in cancer. Trends in Molecular Medicine 8: 385-389.

  • Madrid, L., M. Mayo, J. Reuther, and A. Baldwin (2001). Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-kB through utilization of the IkB kinase (IKK) and activation of the MAP kinase p38. J. Biol. Chem. 276: 18934-18940.

  • Westerheide, S., M. Mayo, V. Anest, J. Hanson, and A. Baldwin (2001). The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G1 transition. Mol. Cell. Biol. 21:  8428-8436.

  • Baldwin, A. (2001). Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kB. J. Clin. Inv. 107: 241-246.

  • Guttridge, D., M. Mayo, L. Madrid, C.-Y. Wang, and A. Baldwin (2000). NF-kB-induced loss of MyoD mRNA: possible role in muscle decay and cachexia. Science 289: 2363-2368.

  • Cogswell, P., D. Guttridge, W. Funkhouser, and A. Baldwin (2000). Selective activation of NF-kB subunits in human breast cancer: potential roles for NF-kB2/p52 and Bcl-3. Oncogene 19: 1123-1131.

  • Guttridge, D., C. Albanese, J. Reuther, R. Pestell, and A. Baldwin (1999). NF-kB controls cell growth and differentiation through transcriptional rgulation of cyclin D1. Mol. Cell. Biol. 19: 5785-5799.

  • Wang, C-Y., J. Cusack, R. Liu, and A. Baldwin (1999). Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kB. Nature Medicine 5:  412-417.